Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped up before the market opened on Thursday . The stock had previously closed at $26.40, but opened at $28.3630. Chugai Pharmaceutical shares last traded at $27.17, with a volume of 7,508 shares trading hands.

Chugai Pharmaceutical Stock Down 1.7%

The business has a fifty day moving average of $24.46 and a 200 day moving average of $24.09. The company has a market cap of $87.51 billion, a P/E ratio of 33.24 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, October 24th. The company reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $2.26 billion for the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%. On average, sell-side analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.